Verrica Q3 net product revenue negative $1.9M; CEO Ted White resigns, replaced by Dr. Rieger

Verrica Pharmaceuticals Inc.

Negative net product revenue of $1.9M in Q3 2024, including $1.7M provision for returns; no ex-factory sales.
Net loss of $22.9M ($0.49 per share) vs $24.8M ($0.54) in Q3 2023; non-GAAP loss $20.2M.
CEO Ted White resigns effective Nov 5; Dr. Jayson Rieger appointed President, CEO, and director.
John Kirby appointed Interim CFO; company engaged Jefferies to advise on strengthening balance sheet.
Restructuring cuts operating expenses ~50%; VP-315 Phase 2 shows 51% complete histologic clearance for BCC.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jayson Rieger

President and Chief Executive Officer

VRCA · Verrica Pharmaceuticals Inc.

Effective: 2024-11-05
Filed: November 4, 2024, 6:59 PM ET

On November 1, 2024, the Board appointed Dr. Jayson Rieger as the Company’s President, Chief Executive Officer, and as member of the Board and designated him as the Company’s principal executive officer, each effective as of the Effective Date.

Departed

Ted White

President and Chief Executive Officer

VRCA · Verrica Pharmaceuticals Inc.

Effective: 2024-11-05
Successor: Jayson Rieger
Filed: November 4, 2024, 6:59 PM ET

On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “ Board ”) effective as of November 5, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jayson Rieger was appointed as President and Chief Executive Officer at Verrica Pharmaceuticals Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On November 1, 2024, the Board appointed Dr. Jayson Rieger as the Company’s President, Chief Executive Officer, and as member of the Board and designated him as the Company’s principal executive officer, each effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ted White resigned as President and Chief Executive Officer at Verrica Pharmaceuticals Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On November 1, 2024, Ted White notified the Company that he will resign from his positions as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “ Board ”) effective as of November 5, 2024

View on SEC.gov

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-250638

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.